دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Influence of Cardiac Remodeling on Clinical Outcomes in Patients With Aortic Regurgitation
Maan Malahfji, MD, a Valentina Crudo, MD,a Yodying Kaolawanich, MD,b Duc T. Nguyen, MD, PHD, c Amr Telmesani, MD, a Mujtaba Saeed, MD,a Michael J. Reardon, MD, a William A. Zoghbi, MD, a Venkateshwar Polsani, MD, d Michael Elliott, MD,e Robert O. Bonow, MD, f Edward A. Graviss, PHD, MPH,c Raymond Kim, MD, b Dipan J. Shah, MD
doi : 10.1016/j.jacc.2023.03.001
Volume 81, Issue 19, 16 May 2023, Pages 1885-1898
Quantitative cardiac magnetic resonance (CMR) outcome studies in aortic regurgitation (AR) are few. It is unclear if volume measurements are beneficial over diameters.
Advances in Risk Stratification of Chronic Aortic Regurgitation: Time for a Change in Guidelines?∗
Anna Sannino, MD, PHD, a,b Maria Chiara Meucci, MD
doi : 10.1016/j.jacc.2023.03.411
Volume 81, Issue 19, 16 May 2023, Pages 1899-1901
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Javed Butler, MD, MPH, MBA, a,b Milton Packer, MD, c,d Tariq Jamal Siddiqi, MD, e Michael B?hm, MD,f Martina Brueckmann, MD,g,h James L. Januzzi, MD,i Subodh Verma, MD, PH D, j Ingrid Gergei, MD,g,k Tomoko Iwata, MS C,l Christoph Wanner, MD, m Jo?o Pedro Ferreira, MD,n,o Stuart J. Pocock, PHD, p Gerasimos Filippatos, MD,q Stefan D. Anker, MD, PHD, r,s Faiez Zannad, MD, PH D
doi : 10.1016/j.jacc.2023.03.390
Volume 81, Issue 19, 16 May 2023, Pages 1902-1914
Empagliflozin reduces the risk of major heart failure outcomes in heart failure with reduced or preserved ejection fraction.
SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place∗
S?ren L. Kristensen, MD, PH D, a Jesper Jensen, MD, P HD, a,b Morten Schou, MD, PHD
doi : 10.1016/j.jacc.2023.03.389
Volume 81, Issue 19, 16 May 2023, Pages 1915-1917
Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction
Rahim Kanji, MBBS,a,b Ying X. Gue, MBBS, PHD, c,d Vassilios Memtsas, MBBS, a,b Neil H. Spencer, P HD, e Diana A. Gorog, MD, PHD
doi : 10.1016/j.jacc.2023.03.388
Volume 81, Issue 19, 16 May 2023, Pages 1918-1932
Spontaneous reperfusion, seen in ∼20% of patients with ST-segment elevation myocardial infarction (STEMI), manifests as normal epicardial flow in the infarct-related artery, with or without ST-segment resolution, before percutaneous coronary intervention (PCI). The drivers mediating this are unknown.
Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants∗
Robert F. Storey, MD, DM, William A.E. Parker, MD, PH D
doi : 10.1016/j.jacc.2023.03.391
Volume 81, Issue 19, 16 May 2023, Pages 1933-1936
Patient-Reported Outcomes After Tetralogy of Fallot Repair
Adrienne H. Kovacs, P HD, a,b Gerald Lebovic, PH D, c Stavroula Raptis, MS, c Samuel Blais, MD, PH D, d,e Christopher A. Caldarone, MD,f Nagib Dahdah, MD,g Frédéric Dallaire, MD, PHD, d,e Christian Drolet, MD,h Jasmine Grewal, MD,i Camille L. Hancock Friesen, MD,j Edward Hickey, MD,f Gauri Rani Karur, MD, k Paul Khairy, MD P HD, l Benedetta Leonardi, MD, m Michelle Keir, MD, n Brian W. McCrindle, MD, MPH, o Syed Najaf Nadeem, MD, p Ming-Yen Ng, MD,q,r Ashish H. Shah, MD, s Edythe B. Tham, MBBS, t Judith Therrien, MD, u Andrew E. Warren, MD,v Isabelle F. Vonder Muhll, MD,w Alexander Van de Bruaene, MD, PH D, x Kenichiro Yamamura, MD, P HD, MS, y Michael E. Farkouh, MD, MS, b Rachel M. Wald, MD
doi : 10.1016/j.jacc.2023.03.385
Volume 81, Issue 19, 16 May 2023, Pages 1937-1950
Comprehensive assessment of tetralogy of Fallot (TOF) outcomes extends beyond morbidity and mortality to incorporate patient-reported outcomes (PROs), including quality of life (QOL) and health status (HS).
Patient-Reported Outcomes in Tetralogy of Fallot: The Potential of the CORRELATE Cohort∗
Michael L. O’Byrne, MD, MSCE
doi : 10.1016/j.jacc.2023.03.386
Volume 81, Issue 19, 16 May 2023, Pages 1951-1953
Multimodality Imaging of Right Heart Function: JACC Scientific Statement
Rebecca T. Hahn, MD, a Stamatios Lerakis, MD, b Victoria Delgado, MD, P HD, c Karima Addetia, MD, d Daniel Burkhoff, MD, PHD, e Denisa Muraru, MD, P HD, f,g Sean Pinney, MD,d Mark K. Friedberg, MD
doi : 10.1016/j.jacc.2023.03.392
Volume 81, Issue 19, 16 May 2023, Pages 1954-1973
Right ventricular (RV) size and function assessed by multimodality imaging are associated with outcomes in a variety of cardiovascular diseases. Understanding RV anatomy and physiology is essential in appreciating the strengths and weaknesses of current imaging methods and gives these measurements greater context.
Reconsidering the Direction of Coronary Revascularization Trials
Gregg W. Stone, MD, a Mario Gaudino, MD, MSCE, PHD
doi : 10.1016/j.jacc.2023.03.387
Volume 81, Issue 19, 16 May 2023, Pages 1974-1978
